Trade Basilea Pharma AG - BSLN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.95 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.013571% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.008651% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | CHF | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Switzerland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 39.85 |
| Open | 39.25 |
| 1-Year Change | 14.1% |
| Day's Range | 39.05 - 40.45 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 4, 2024 | 39.85 | -0.85 | -2.09% | 40.70 | 40.85 | 39.00 |
| Dec 3, 2024 | 40.50 | -0.45 | -1.10% | 40.95 | 41.20 | 40.00 |
| Dec 2, 2024 | 40.00 | -1.55 | -3.73% | 41.55 | 41.70 | 40.00 |
| Nov 29, 2024 | 41.55 | 0.40 | 0.97% | 41.15 | 41.60 | 40.40 |
| Nov 28, 2024 | 41.40 | 0.45 | 1.10% | 40.95 | 41.65 | 40.45 |
| Nov 27, 2024 | 40.60 | 0.90 | 2.27% | 39.70 | 40.80 | 39.65 |
| Nov 26, 2024 | 40.30 | -1.00 | -2.42% | 41.30 | 41.75 | 39.70 |
| Nov 25, 2024 | 41.90 | 0.65 | 1.58% | 41.25 | 41.90 | 40.20 |
| Nov 22, 2024 | 40.45 | -0.05 | -0.12% | 40.50 | 41.25 | 39.90 |
| Nov 21, 2024 | 40.55 | 0.50 | 1.25% | 40.05 | 40.55 | 39.05 |
| Nov 20, 2024 | 39.80 | 0.80 | 2.05% | 39.00 | 40.55 | 39.00 |
| Nov 19, 2024 | 39.45 | -0.25 | -0.63% | 39.70 | 39.80 | 38.30 |
| Nov 18, 2024 | 38.95 | -0.60 | -1.52% | 39.55 | 40.05 | 38.70 |
| Nov 15, 2024 | 39.65 | -0.10 | -0.25% | 39.75 | 40.10 | 38.90 |
| Nov 14, 2024 | 40.60 | -0.15 | -0.37% | 40.75 | 40.85 | 39.85 |
| Nov 13, 2024 | 40.70 | -0.10 | -0.25% | 40.80 | 40.95 | 39.90 |
| Nov 12, 2024 | 40.30 | -1.20 | -2.89% | 41.50 | 41.50 | 40.20 |
| Nov 11, 2024 | 40.95 | -1.45 | -3.42% | 42.40 | 42.40 | 40.95 |
| Nov 8, 2024 | 41.30 | -0.40 | -0.96% | 41.70 | 42.45 | 41.25 |
| Nov 7, 2024 | 42.35 | -0.10 | -0.24% | 42.45 | 42.85 | 41.50 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Basilea Company profile
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. It launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Basilea Pharmaceutica AG revenues increased 16% to SF148.1M. Net loss decreased 54% to SF6.8M. Revenues reflect Japan segment increase of 41% to SF56.5M, Republic of Ireland segment increase of 9% to SF62.1M. Lower net loss reflects Research & development expenses, net - B decrease of 4% to SF91.6M (expense), Stock-based Compensation in SGA decrease of 6% to SF1.7M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
Hegenheimermattweg 167b
ALLSCHWIL
BASEL-LANDSCHAFT 4123
CH
News
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
09:32, 4 December 2024
Silver price forecast 2025 and beyond: Third party price target
Rising interest rates and a strong dollar pushed silver to a two-year last September, but what lies ahead?
16:00, 3 December 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
16:41, 28 November 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com